We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.02B
AUM Growth
+$67.6M
Cap. Flow
+$92.8M
Cap. Flow %
9.11%
Top 10 Hldgs %
47.33%
Holding
173
New
45
Increased
25
Reduced
30
Closed
56

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$31.8M
2
FOLD
Amicus Therapeutics
FOLD
+$26.7M
3
ZBH icon
Zimmer Biomet
ZBH
+$24.4M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$22.7M
5
INSM icon
Insmed
INSM
+$21.6M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$17.8M
2
TSRO
TESARO, Inc.
TSRO
+$15.8M
3
EXAS
Exact Sciences
EXAS
+$12.7M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.29%
2 Miscellaneous 14.83%
3 Consumer Staples 1.81%
4 Financials 1.05%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDSO
151
DELISTED
Medidata Solutions, Inc.
MDSO
– –
-2,802
Closed -$152K
INSY
152
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-12,306
Closed -$255K
ADYX
153
DELISTED
Adynxx Inc
ADYX
– –
-13,077
Closed -$6.47M
HZNP
154
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-9,120
Closed -$138K
ECYT
155
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-435,000
Closed -$10.4M
KERX
156
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-275,000
Closed -$4.69M
IPXL
157
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-5,962
Closed -$158K
ENZY
158
DELISTED
Enzymotec Ltd
ENZY
– –
-214,219
Closed -$4.72M
ALR
159
DELISTED
Alere Inc
ALR
– –
-3,700
Closed -$127K
SCAI
160
DELISTED
Surgical Care Affiliates, Inc.
SCAI
– –
-7,472
Closed -$230K
XNPT
161
DELISTED
XENOPORT, INC.
XNPT
– –
-50,000
Closed -$258K
OCR
162
DELISTED
OMNICARE INC
OCR
– –
-1,732
Closed -$103K
ITMN
163
CALL
DELISTED
INTERMUNE INC
ITMN
– –
-100,000
Closed -$3.35M
IDIX
164
CALL
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
– –
-300,000
Closed -$1.81M
CHTP
165
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-1,301,639
Closed -$7.18M
VVUS
166
PUT
DELISTED
Vivus Inc
VVUS
– –
-10,000
Closed -$594K
MDVN
167
DELISTED
MEDIVATION, INC.
MDVN
– –
-63,800
Closed -$2.05M
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Perceptive Advisors held 173 positions worth $1.02B, up 7.1% from $952M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $92.8M of net new capital in Q2 2014, opening 45 new positions and adding to 25 existing holdings. Its largest new stake was Zimmer Biomet: 249,775 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $17.8M trimmed.

  • Perceptive Advisors's largest Q2 2014 buy was Zimmer Biomet: 249,775 shares worth $25.2M.
  • Perceptive Advisors added most to QUESTCOR PHARMA INC in Q2 2014, an estimated $31.8M increase.
  • Perceptive Advisors's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $17.8M.
  • Perceptive Advisors fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $10.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.02B portfolio in Q2 2014.
  • Perceptive Advisors opened 45 new positions and closed 56 in Q2 2014.
  • Perceptive Advisors's portfolio value rose 7.1% quarter-over-quarter to $1.02B.

Based on Perceptive Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.